Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.

Michael C. Lowe,Brian Olson,Anthony P. Martinez,Jacklyn Hammons,Keith A. Delman,Melinda L. Yushak,Melanie Allor,Christine Reilly,Crystal Mallow,Elizabeth E. Evans,Terrence L. Fisher,Gregory B. Lesinski,Ragini R. Kudchadkar

Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.

2020

Michael C. Lowe
Brian Olson
Anthony P. Martinez
Jacklyn Hammons
Keith A. Delman
Melinda L. Yushak
Melanie Allor
Christine Reilly
Crystal Mallow
Elizabeth E. Evans
Terrence L. Fisher
Gregory B. Lesinski
Ragini R. Kudchadkar

10061Background: SEMA4D has broad immunomodulatory effects in the tumor microenvironment (TME); blocking SEMA4D in combination with checkpoint inhibitors (CI) promotes immune infiltration, reduces ...

Keywords:

Oncology
Internal medicine
Pathology
Nivolumab
Biomarker (medicine)
in patient
metastatic melanoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations